Cargando…
Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis
BACKGROUND: Cardiomyocytes differentiated from human pluripotent stem cells can serve as an unexhausted source for a cellular cardiac disease model. Although small molecule–mediated cardiomyocyte differentiation methods have been established, the differentiation efficiency is relatively unsatisfacto...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721819/ https://www.ncbi.nlm.nih.gov/pubmed/28971953 http://dx.doi.org/10.1161/JAHA.116.005295 |
_version_ | 1783284888769658880 |
---|---|
author | Qiu, Xiao‐Xu Liu, Yang Zhang, Yi‐Fan Guan, Ya‐Na Jia, Qian‐Qian Wang, Chen Liang, He Li, Yong‐Qin Yang, Huang‐Tian Qin, Yong‐Wen Huang, Shuang Zhao, Xian‐Xian Jing, Qing |
author_facet | Qiu, Xiao‐Xu Liu, Yang Zhang, Yi‐Fan Guan, Ya‐Na Jia, Qian‐Qian Wang, Chen Liang, He Li, Yong‐Qin Yang, Huang‐Tian Qin, Yong‐Wen Huang, Shuang Zhao, Xian‐Xian Jing, Qing |
author_sort | Qiu, Xiao‐Xu |
collection | PubMed |
description | BACKGROUND: Cardiomyocytes differentiated from human pluripotent stem cells can serve as an unexhausted source for a cellular cardiac disease model. Although small molecule–mediated cardiomyocyte differentiation methods have been established, the differentiation efficiency is relatively unsatisfactory in multiple lines due to line‐to‐line variation. Additionally, hurdles including line‐specific low expression of endogenous growth factors and the high apoptotic tendency of human pluripotent stem cells also need to be overcome to establish robust and efficient cardiomyocyte differentiation. METHODS AND RESULTS: We used the H9–human cardiac troponin T–eGFP reporter cell line to screen for small molecules that promote cardiac differentiation in a monolayer‐based and growth factor–free differentiation model. We found that collaterally treating human pluripotent stem cells with rapamycin and CHIR99021 during the initial stage was essential for efficient and reliable cardiomyocyte differentiation. Moreover, this method maintained consistency in efficiency across different human embryonic stem cell and human induced pluripotent stem cell lines without specifically optimizing multiple parameters (the efficiency in H7, H9, and UQ1 human induced pluripotent stem cells is 98.3%, 93.3%, and 90.6%, respectively). This combination also increased the yield of cardiomyocytes (1:24) and at the same time reduced medium consumption by about 50% when compared with the previous protocols. Further analysis indicated that inhibition of the mammalian target of rapamycin allows efficient cardiomyocyte differentiation through overcoming p53‐dependent apoptosis of human pluripotent stem cells during high‐density monolayer culture via blunting p53 translation and mitochondrial reactive oxygen species production. CONCLUSIONS: We have demonstrated that mammalian target of rapamycin exerts a stage‐specific and multifaceted regulation over cardiac differentiation and provides an optimized approach for generating large numbers of functional cardiomyocytes for disease modeling and in vitro drug screening. |
format | Online Article Text |
id | pubmed-5721819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57218192017-12-12 Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis Qiu, Xiao‐Xu Liu, Yang Zhang, Yi‐Fan Guan, Ya‐Na Jia, Qian‐Qian Wang, Chen Liang, He Li, Yong‐Qin Yang, Huang‐Tian Qin, Yong‐Wen Huang, Shuang Zhao, Xian‐Xian Jing, Qing J Am Heart Assoc Original Research BACKGROUND: Cardiomyocytes differentiated from human pluripotent stem cells can serve as an unexhausted source for a cellular cardiac disease model. Although small molecule–mediated cardiomyocyte differentiation methods have been established, the differentiation efficiency is relatively unsatisfactory in multiple lines due to line‐to‐line variation. Additionally, hurdles including line‐specific low expression of endogenous growth factors and the high apoptotic tendency of human pluripotent stem cells also need to be overcome to establish robust and efficient cardiomyocyte differentiation. METHODS AND RESULTS: We used the H9–human cardiac troponin T–eGFP reporter cell line to screen for small molecules that promote cardiac differentiation in a monolayer‐based and growth factor–free differentiation model. We found that collaterally treating human pluripotent stem cells with rapamycin and CHIR99021 during the initial stage was essential for efficient and reliable cardiomyocyte differentiation. Moreover, this method maintained consistency in efficiency across different human embryonic stem cell and human induced pluripotent stem cell lines without specifically optimizing multiple parameters (the efficiency in H7, H9, and UQ1 human induced pluripotent stem cells is 98.3%, 93.3%, and 90.6%, respectively). This combination also increased the yield of cardiomyocytes (1:24) and at the same time reduced medium consumption by about 50% when compared with the previous protocols. Further analysis indicated that inhibition of the mammalian target of rapamycin allows efficient cardiomyocyte differentiation through overcoming p53‐dependent apoptosis of human pluripotent stem cells during high‐density monolayer culture via blunting p53 translation and mitochondrial reactive oxygen species production. CONCLUSIONS: We have demonstrated that mammalian target of rapamycin exerts a stage‐specific and multifaceted regulation over cardiac differentiation and provides an optimized approach for generating large numbers of functional cardiomyocytes for disease modeling and in vitro drug screening. John Wiley and Sons Inc. 2017-10-02 /pmc/articles/PMC5721819/ /pubmed/28971953 http://dx.doi.org/10.1161/JAHA.116.005295 Text en © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Qiu, Xiao‐Xu Liu, Yang Zhang, Yi‐Fan Guan, Ya‐Na Jia, Qian‐Qian Wang, Chen Liang, He Li, Yong‐Qin Yang, Huang‐Tian Qin, Yong‐Wen Huang, Shuang Zhao, Xian‐Xian Jing, Qing Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis |
title | Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis |
title_full | Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis |
title_fullStr | Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis |
title_full_unstemmed | Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis |
title_short | Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis |
title_sort | rapamycin and chir99021 coordinate robust cardiomyocyte differentiation from human pluripotent stem cells via reducing p53‐dependent apoptosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721819/ https://www.ncbi.nlm.nih.gov/pubmed/28971953 http://dx.doi.org/10.1161/JAHA.116.005295 |
work_keys_str_mv | AT qiuxiaoxu rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT liuyang rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT zhangyifan rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT guanyana rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT jiaqianqian rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT wangchen rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT lianghe rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT liyongqin rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT yanghuangtian rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT qinyongwen rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT huangshuang rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT zhaoxianxian rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis AT jingqing rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis |